# Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies

> **NCT04406948** · PHASE2 · WITHDRAWN · sponsor: **MGC Pharmaceuticals d.o.o**

## Conditions studied

- Resistant Epilepsy, Drug
- Adolescent Epilepsy
- Children Epilepsy
- Children and Adolescents With Resistant Epilepsies

## Interventions

- **DRUG:** MGCND00EP1
- **DRUG:** Placebo
- **DIAGNOSTIC_TEST:** ECG
- **DIAGNOSTIC_TEST:** EEG
- **DIAGNOSTIC_TEST:** Blood and urine collection

## Key facts

- **NCT ID:** NCT04406948
- **Lead sponsor:** MGC Pharmaceuticals d.o.o
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-30
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-05-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Failure to overcome bureaucratic obstacles within timeframe.
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04406948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04406948, "Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04406948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*